Roche Holding AG (RHHBY) Wednesday said it received CE Mark for its Elecsys pTau181 test, a minimally invasive blood test to help rule out Alzheimer's disease.
The test, which has been developed in collaboration with Eli Lilly and Company, measures phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer's disease. This test will avoid the need for further confirmatory investigation for patients who test negative.
The CE Mark for the Elecsys pTau181 blood test was based on data from a study which showed the test was able to rule out Alzheimer's disease with 93.8% accuracy.
"With Elecsys pTau181, doctors can give patients and their caregivers the clarity they need when establishing the cause of cognitive decline. By enabling an earlier and less invasive diagnosis, this test has the potential to improve patient outcomes and decrease costs for healthcare systems worldwide," said Matt Sause, CEO of Roche Diagnostics.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.